Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEvaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
Gynecologic Oncology, 07/03/08
Miller DS et al. - In a trial to estimate the anti-tumor activity of pemetrexed in pts with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity, it was found that pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cervical cancer that has failed prior chemotherapy
Methods- Pts must have had advanced or recurrent measurable carcinoma of the cervix, and failed 1 prior chemotherapy regimen
- Pemetrexed at a dose of 900 mg/m2 was to be administered as an IV infusion over 10 min every 21 days
- 29 pts were entered by 10 member institutions of the GOG
- 2 pts did not receive treatment and thus were inevaluable
- 128 cycles were administered with 37% of pts receiving 6 or more cycles
- Treatment was well tolerated overall; more serious toxicities (grade 3 and 4) included anemia in 41%, leukopenia in 30%, neutropenia in 26%, and infection in 26%
- No treatment-related deaths were reported
- 4 pts had partial responses with a median response duration of 4.4 months
- Response rate for non-radiated or radiated disease sites was 25% and 7%, respectively
- 16 pts had stable disease and 7 pts had increasing disease
- Median progression-free survival was 3.1 months and overall survival was 7.4 months
Related Articles
The consistency of Fletcher-Suit applicator geometry and of the rectal probe's position in high dose rate brachytherapy treatment fraction of cervix carcinoma
Journal of Contemporary Brachytherapy, 10/13/09
Relevance Score: 89%
Breast cancer with synchronous massive metastasis in the uterine cervix
Archives of Gynecology and Obstetrics, 11/02/09
Relevance Score: 87%
Spread of Squamous Cell Carcinoma From the Thumb to the Small Finger via the Flexor Tendon Sheaths
The Journal of Hand Surgery, 11/16/09
Relevance Score: 85%
Dermatomyositis and small cell carcinoma of the bladder
Canadian Family Physician, 10/14/09
Relevance Score: 85%
Invasive papillary carcinoma of the male breast: Report of a rare case and review of the literature
Journal of Cancer Research and Therapeutics, 10/28/09
Relevance Score: 84%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/04/09
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Vaginal Schwannoma in a case with uterine myoma
Annals of Diagnostic Pathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor